| Targeted degradation of the enhancer lysine acetyltransferases CBP and p300 R Vannam, J Sayilgan, S Ojeda, B Karakyriakou, E Hu, J Kreuzer, ... Cell Chemical Biology 28 (4), 503-514. e12, 2021 | 99 | 2021 |
| High resolution vessel wall MRI and vasculopathy related to herpes zoster ophthalmicus JW Song, S Ojeda, JM Romero Clinical Imaging 50, 336-339, 2018 | 7 | 2018 |
| DrugMap: A quantitative pan-cancer analysis of cysteine ligandability M Takahashi, HB Chong, S Zhang, TY Yang, MJ Lazarov, S Harry, ... Cell 187 (10), 2536-2556. e30, 2024 | 5 | 2024 |
| Patient, defect, and surgical factors influencing use of ancillary procedures after facial Mohs repairs RA Neuner, AP Sclafani, K Minkis, A Obayemi, K Navrazhina, B Cressey, ... Facial Plastic Surgery 37 (03), 390-394, 2021 | 2 | 2021 |
| Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity PK Tiwari, SR Doda, R Vannam, M Hudlikar, DA Harrison, S Ojeda, S Rai, ... Bioorganic & Medicinal Chemistry Letters 102, 129676, 2024 | | 2024 |
| Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network MA Toure, K Motoyama, Y Xiang, J Urgiles, F Kabinger, AS Koglin, ... bioRxiv, 2024.05. 14.593352, 2024 | | 2024 |
| Development of p300-targeting PROTAC degraders with enhanced selectivity and onset of degradation GP Marsh, S Goggins, D Bosnakovski, M Kyba, S Ojeda, DA Harrison, ... Cancer Research 83 (7_Supplement), 3841-3841, 2023 | | 2023 |
| Targeted degradation of the enhancer lysine acetyltransferases CBP and p300 S Ojeda, R Vannam, J Sayilgan, B Karakyriakou, E Hu, J Kreuzer, ... Cancer Research 81 (13_Supplement), 1146-1146, 2021 | | 2021 |
Barbara KarakyriakouGeisel School of Medicine, Dartmouth CollegeVerified email at dartmouth.edu
